Patient with recurrent glioblastoma began optune treatment on (b)(6) 2014.On (b)(6) 2014, patient was hospitalized for general physical health deterioration.On (b)(6) 2014, novocure was informed that the patient had died that same day.No additional information was provided.No adverse events associated with device use were reported.Per device logfile review, the last day of optune use was (b)(6) 2014 at 07:40 and device was functioning as per normal operating conditions.On (b)(6) 2014, prescribing physician informed novocure that the patient had been lost to follow-up and had not been seen at the clinic since the optune therapy initiation visit.Therefore, cause of death was not known and a causality assessment was not provided.
|